Nano-X director sells 678 shares at $1.65
Nano-X Imaging Ltd. director Alroy Erez sold 678 ordinary shares on June 10, 2026 at $1.65 per share in open-market transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Nano-X Imaging Ltd. director Alroy Erez sold 678 ordinary shares on June 10, 2026 at $1.65 per share in open-market transactions. A footnote explains that the reported sale of ordinary shares was used to cover tax liabilities arising from the vesting of restricted share units.
Following these transactions, Erez continues to hold ordinary shares tied to RSU grants, including 6,753 and 17,075 ordinary shares remaining or issuable under two separate awards. He also holds stock options over 10,000 ordinary shares at an exercise price of $11.52 expiring on December 31, 2033, and options over 50,000 ordinary shares at an exercise price of $17.63 expiring on December 28, 2032.
Insider Trade Summary
Net Seller: 678 shares
Net Sell
4 txns
Insider
Alroy Erez
Role
Director
Sold
678 shs ($1K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 209 | $1.65 | $344.85 |
| Sale | Ordinary Shares | 469 | $1.65 | $773.85 |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 17,075 shares (Direct);
Stock Option (right to buy ordinary shares) — 60,000 contracts (Direct)
Footnotes (6)
- F1. The transaction reported in this row involved the sale of ordinary shares to cover tax liabilities arising from the vesting of restricted share units ("RSUs").
- F2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2024. Currently, 6,753 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 7,792 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 649.33 underlying ordinary shares per quarter) such that all such 7,792 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2027.
- F3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person by the Issuer that began vesting on December 10, 2025. Currently, 17,075 ordinary shares constitute the remainder of the ordinary shares held by, or issuable to, the Reporting Person under the subject grant. The 17,544 RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis over twelve calendar quarters (for 1,462 underlying ordinary shares per quarter) such that all such 17,544 RSUs - reduced by RSUs for which underlying shares have been sold to cover tax liability - will be vested by December 10, 2028.
- F4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- F5. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of appointment of the Reporting Person to the Issuer's Board of Directors on June 30, 2022, such that all options reported in this row will be exercisable by the four-year anniversary of that appointment date (June 30, 2026).
- F6. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable by the four-year anniversary of that grant approval date (August 14, 2027).
Key Figures
Shares sold: 678 shares
Sale price: $1.65 per share
Remaining RSU-related shares (grant 1): 6,753 ordinary shares
+5 more
8 metrics
Shares sold
678 shares
Ordinary shares sold on June 10, 2026 at $1.65
Sale price
$1.65 per share
Open-market sale of 678 ordinary shares
Remaining RSU-related shares (grant 1)
6,753 ordinary shares
Remainder held by or issuable to Erez under RSU grant beginning December 10, 2024
Remaining RSU-related shares (grant 2)
17,075 ordinary shares
Remainder held by or issuable to Erez under RSU grant beginning December 10, 2025
Option position 1
10,000 shares at $11.52
Stock options over ordinary shares expiring December 31, 2033
Option position 2
50,000 shares at $17.63
Stock options over ordinary shares expiring December 28, 2032
Original RSU grant 1
7,792 RSUs
Vesting quarterly over twelve quarters to be fully vested by December 10, 2027
Original RSU grant 2
17,544 RSUs
Vesting quarterly over twelve quarters to be fully vested by December 10, 2028
Key Terms
restricted share units ("RSUs"), open-market sale, Stock Option (right to buy ordinary shares), vesting, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale", "transaction_code_description": "Sale in open market or private transaction""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"RSUs originally granted vest (and settle for underlying ordinary shares) on an equal, quarterly basis"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise price financial
"exercisePrice": "11.5200" and "17.6300" for stock options over ordinary shares"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Nano-X Imaging (NNOX) director Alroy Erez report in this Form 4?
Alroy Erez reported selling 678 ordinary shares of Nano-X Imaging on June 10, 2026 at $1.65 per share. The activity is disclosed as open-market sales with related details on his remaining share and option holdings.
How do the Nano-X Imaging (NNOX) RSU grants to Alroy Erez vest over time?
The filing notes RSU grants of 7,792 and 17,544 units vest quarterly over twelve calendar quarters. They began vesting on December 10, 2024 and December 10, 2025, respectively, with full vesting expected by 2027 and 2028, subject to shares sold for tax.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates